Advanced Med. - kaum beachteter Rebound Kandidat

Webseite: www.avmd.com.au/


und anfangen werde ich mal mit dem letzten Q-Bericht vom 23.11.09

www.pinksheets.com/edgar/GetFilingHtml?FilingID=6909080

Highlights:

TOTAL CURRENT ASSETS        30,068,523$          

Common stock, par value $0.001 per share,  
90,000,000 shares authorized,
53,507,450 issued and outstanding as at September 30, 2009

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY                       $  52,082,210  

NET REVENUE                                                                             $  14,507,711  

COST OF REVENUE                                                                       (3,291,231  )                                
GROSS PROFIT                                                                             11,216,480          


Net Comprehensive Income (Loss)                                            $  1,995,828                                  
Earnings per common share – basic & diluted                           $  0.02    


aktuelle Marktkap.

$2,675,372 as of Jan 22, 2010
bei Outstanding Shares 53,507,450 siehe letzter Q-Bericht

fassen wir zusammen: KGV 2,5   KBV :0,09 - unglaublich, aber nach letzdem Stand Fakt


Gruß,

Hummel

Mr. Khan is AVMD’s Chief Operating Officer. Mr. Khan has served as Secretary and a Director of the Company since April 7, 2005. Mr. Khan also served as the chief operating officer of AMI Australia since July 1, 2005. From 2001 to July 1, 2005, Mr. Khan was the General Manager of AMI Australia, AVMD’s chief operating subsidiary. Previously, Khan founded, was the director and was the sole shareholder of Australian Momentum Health Pty Limited, a provider of impotency treatments in Australia and a predecessor of AMI Australia. Before founding Australian Momentum Health, he was Sales Manager and Operations Manager for On Clinic International Pty Limited. Mr. Khan holds a Masters degree in Commerce and Accounting and has been involved in the sexual dysfunction industry for over 10 years.


Dilip Shrestha


Chief Financial Officer
Mr. Shrestha is the Chief Financial Officer of AVMD. Mr. Shrestha joined AMI Australia, AVMD’s chief operating subsidiary, in 2001 as a financial controller and was named Chief Financial Officer of AVMD on April 7, 2005. Prior to joining AMI Australia, he was a financial officer with Australian Momentum Health Pty Limited (a predecessor company of AMI Australia), a position he held from 1999 until 2001. He began his career as an operations and information technology manager with Kalinchowk Trading Company Ltd. Mr. Shrestha holds a Master’s degree in E-Commerce, a Graduate Diploma of Information Systems and E-Commerce and a Bachelor of Business Accounting. Mr. Shrestha is the co-developer of AVMD’s in-house proprietary enterprise software which is designed to oversee and manage AVMD’s business operations and which incorporates a customer management system that tracks customers from first contact to treatment program completion.


Hummel
 

AVMD’s wholly owned subsidiary, AMI Australia operates a centralized call center and twenty medical centers and sales offices throughout Australia, New Zealand, China and the United Kingdom.

AVMD’s core assets includes significant unique proprietary intellectual property developed during our subsidiaries’ business 16 years operating history. Our proprietary intellectual property includes:

Customer database of more than 400,000 patients.
Clinic Management System software (CMS) & Web based Clinic Management System software (CMS Web) which provides:
Customer profiles;
Financial history and management systems;  
Logistics management;  
Customer Relationship Management (CRM);
Clinic booking system; and
Micro-management and internal controls.
Specific drug formulations.
Dosing protocols, treatment manuals and methodologies.
An Australian innovation patent (Australian Innovation Patent No 2005100183, which patent is due to expire on July 9, 2012), an Australian standard patent application (Australian standard patent application No. 2004222783), a worldwide PCT patent application Patent No PCT/AU2004/000931 (WO 2005/004855 A1)) filed with IP Australia and the subsequent individual country applications filed in the United States, Europe, Japan, the People’s Republic of China, India and New Zealand. The patents relate to various methods of treatment delivery via nasal (mucosal) inhalation and topical application of certain formulations used in AVMD’s treatments for premature ejaculation. The patents and associated formulations are integral to those treatments. AVMD’s impotence and erectile dysfunction treatments are not patent protected.
Call center scripts.

Marketing and sales collateral including copyright in our advertisements.
Business trademarks
Additional trade secrets, technical information and detailed market knowledge and understanding.
Ownership of Intellectual Medical Technologies Pty Limited (IMT).

Hummel

zwar schon 2 Monate alt, aber daran hat sich bis jetzt ja auch noch nichts geändert:

Posted by: tvmetguy    Date: Thursday, November 26, 2009 7:41:32 AM  
In reply to: None  Post # of 871      

AVMD-Reasons For Continued Rise

1) Equity value is .37 (22 Mil assets)

2) Book value is .50

3) Fair value is 1.20 (EPS .08, PE 15)

4) It's traded mainly between .05 and .35 in the last 12 months so most hold shares at these levels already so Tuesdays large rise only brough most investors to "even" on the stock.

5) After a 477% increase on Tuesday, it consolidated at the resistance levlel of .19, only a 19% decrease.

6) The next resistance level after .19 is .35 which was they high within the last 12 months.

7) There is no resistance after .35, of which the all time high is 2.50 a few years ago

8) Their bottom line is increasing due to cost cutting and it appears that the CEO has turned the company around from a poor FY 09 that ended on June 30th 2009.

9) The bottom line is increasing because their new UK division has gone from start up to profitability for FY 10

10) They now have major streams of revenue in 2 differnt countries and dropped failing business in Japan and China

11) The weak dollar allows for favorable exchange rates from the foreign currency they reieve their revenue in which could lead to much higher profits than expected.

12) They don't dilute.

13) Low float.

14) $55 mil in revenue, likely $8-10 mil in profit for FY 10 coming up, much higher than ever before (growth into UK helping)

15) It was way oversold because of a bad FY 09 in which they spent millions on new offices in the UK which ultimately now the spending is done and revenue/profit has begun.

16) The dollar will remain weak for FY 10.

17) I don't know of any other drug/company including the major commercial ones that deal with premature ejaculation (PE) and this is where their business is growing the most which obviously makes sense if nobody else deals with it. Their erectile dysfunction drug is losing steam to Cialis and Viagra, but still men who don't want to go to a practicioner for those pills still call them over the phone to buy their formulated nasal spray for ED.

wie man sehen kann sind wir wieder am Ausgangspunkt des letzten Anstiegs

Hummel

der nächste Q-Bericht sollte in den nächsten 3-4 Wochen rauskommen - im Jahr 2009 war es der 17-02-09.

sollte sich der nächste Q-Bericht auch nur einigermaßen an dem letzten orientieren sehen wir hier schnelle und heftige Kurssteigerungen.
Man kann anhand des oben gezeigten Charts sehr gut sehen was ein bisschen Volumen ausmachen kann.

AVMD ist im überverkauften Bereich und hat einiges an Potenzial - siehe Fakten - Posting #1

Schaut Euch die Company und die letzten Q-Berichte an und entscheidet was Ihr daraus macht, dies ist mein Invest der nächsten Wochen.

Viel Erfolg,

Hummel

Posted by: kuwlness    Date: Sunday, January 10, 2010 10:19:31 PM  

Advanced Medical Institute's impotence ad most played TV ad of 2009

An ad for Advanced Medical Institute for the treatment of impotence was the most played TV advertisement in 2009, followed by two Optus ads promoting its bundling packages.

The top ten list, collated by Xtreme Information, also saw vitamin company Ethical Nutrients feature twice for its Inner Health Plus and Ethical IBS (irritable bowel syndrome) Support brands.

Most played TV ads of the year:

Advanced Medical Institute
Optus, bundling packages
Optus, bundling packages
Ethical Nutrients – Inner Health Plus
Ethical Nutirents – IBS Support
Raid (What’s New)
O’Brien Glass
Free TV Australia
Lavalife
Kresta

1. Advanced Medical Institute

The most played TV ad of the year was AMI’s treatment of men who suffer from premature or erection problems. The advertiser also took out three spots in the Advertising Standards Bureau’s top ten list of the year’s most complained about ads, for its radio and outdoor creatives.

mumbrella.com.au/advanced-medical-institute-impotence-ad-most-pla­yed-tv-ad-of-2009-14753


Hummel

da hast du uns mal wieder mit guten Informationen versorgt.

Auf dich ist halt verlass.

muenther

Ich habe mir mal den Teil "The Future" auf deren Homepage zu gemüte geführt.


"Eines der Ziele von AVMD ist es, die Rechweite der innovativen Therapie Programme über Australien, Neuseeland, China und Großbritanien zu erweitern. Wir erforschen die Wachstumschancen in Asien, Europa sowie in Großbritanien. Seit dem 15.September 2008 bauen wir Behandlungszentren in GB und schließen Verträge mit unabhängigen Ärzten und Apotheken ab und starteten eine Landesweite Informacial Kampange.

Aufgrund der vorhandenen australischen und weltweiten Marktinformationen über den Markt der sexuellen Funktionsstörungen und anhand unserer Analysen der Wachstumschancen des Marktes in den Vereinigten Staaten von Amerika und der Rest der Welt sehen wir in den kommenden Jahren große Wachstumsmöglichkeiten in diesen Märkten."



Ich würde sagen wir sind hier in einem Wert mit Zukunft. Ich kann da zwar noch nicht wirklich mitreden jedoch die Herren Ü40 in unserer Gruppe bestimmt ;)

Also, nichts für ungut
muenther

AVMD going big. .40 shareholder equity, monster Q earnings on the horizon. Get in before the momo crowds run it up to the .30s again.

muenther

es kann sich nur um Tage handeln bis der Q-Bericht rauskommt :-)

Hummel

stark - wenige Aktien im Float zu haben

seit Threaderöffnung 180% - LOL

also manchmal liege ich gar nicht so daneben :-)

Gruß,

Hummel

THIN - very THIN

Erst einmal vielen Dank für das Reinstellen Muenther -
ich schrieb hier als der Kurs bei 0,05$ stand mit allen Fakten ect. - und alle nur wieder zugeschaut -
man man man - ich glaube wir lassen das in Zukunft und traden unsere Werte in der interenen Gruppe

Gruß

Hummel

da hast Du zu 100%, wir haben zwar schon 200% Gewinn, recht :-)

Wenn niemand etwas vom Kuchen abhaben möchte essen wir ihn halt allen (sprich in der Gruppe)

Viele Grüße
muenther

mach es bitte nicht!
sitze an der seitenlinie
und warte auf frisches kapital!

:)))))

hier ist jetzt Luft bis 0,33$

Gruß,

Hummel

Bitte auch weiterhin hier posten. Verfolge auch alles mit, nur kann ich im Mom nicht investieren.

Danke für die vielen Beiträge!

...woher hast Du eigentlich deine Spürnase geerbt?

da hat man mir an der Börse ein paar Jahre "draufgehauen" - und da man aus Fehlern lernen sollte, versuche ich meine Hausaufgaben zu machen.

Meine Watchliste umfasst in etwa 100 Werte die wöchentlich aktuallisiert werden, und da ist fast immer ein guter dabei :-)

Alles Arbeit, aber das brauche ich Dir ja nicht zu erzählen

lg,

Hummel

das sich jeder Interessent mal durchlesen sollte:

Posted by: stervc    Date: Sunday, February 14, 2010 11:34:05 AM  


AVMD/Boston MedGroup Comparison & Valuation…

AVMD is very similar to the Boston Medical Group. Boston Med Group’s market is primarily the US while AVMD’s market is primarily Australia, New Zealand, China and the United Kingdom. I have a feeling that marketing in the US is coming. AVMD is like an international version of the Boston Medical Group as could be seen and compared below:

Boston Medical Group
www.BostonMedicalGroup.com
www.bostonmedicalgroup.com/sitemap
For over 10 years Boston Medical Group’s network of independent physicians has dedicated its practices to treating Erectile Dysfunction and Premature Ejaculation. Using The Boston Method, a proprietary treatment program, the physicians provide personalized treatment programs that enable most men to see results within minutes. Last year alone the network treated over 30,000 men across the United States.

Advanced Medical Institute, Inc. (AVMD)
www.avmd.com.au/
www.amiaustralia.com.au/
AMI Australia, was founded in February 2001 with the acquisition of two chains of medical clinics providing treatments relating to male sexual dysfunction. AMI Australia has become an important provider of treatment programs for erectile dysfunction (ED) and premature ejaculation (PE) in Australia, having treated or counseled more than 400,000 patients in the past 16 years. …

… AMI Australia operates a major modern centralized call center and 20 specialist medical clinics throughout Australia, New Zealand, China and the United Kingdom, and has more than 270 staff members, including more than 50 licensed medical personnel. …

**************************************************

As for its valuation, with AVMD trading on the OTCBB and filing on a regular basis, much of its valuation calculations have already been derived for us. As indicated below in the last 10Q filed on 11/23/2009, observe the highlights I have made mention of below:

knobias.10kwizard.com/...SEQ=&SQDESC=SECTION_BODY&exp=
** Outstanding Shares (OS) = 53,507,450 shares since Sep 30, 2006 (no dilution concerns)
** TOTAL STOCKHOLDERS’ EQUITY = $20,106,443
** NET REVENUE = $14,507,711
** Earnings Per Share (EPS); basic & diluted = $0.02

That .02 per share EPS is for only one quarter; its third quarter. If you were to annualize that .02 per share EPS, that would give you an EPS of .08 per share for the year. Multiplied by a 12 conservative P/E Ratio and that would give you a price valuation of .96 per share for AVMD derived by...

12 x .08 Annualized EPS = .96 per share valuation

There is a good chance to believe that AVMD will generate enough Income to continue making .02 per share from further researching its historical chart below to see its growth in Income since FY 07:

www.avmd.com.au/index.aspx?Action=AboutAVMD


Although the 3rd Qtr Revenues are not indicated on the chart, from what was filed in their last 10Q filing for the 3rd Qtr, we know that they made $14,507,711 which was higher than the $13,216,784 reflected for the previous 2nd Qtr FY09. What’s further indicated is that AVMD has generated a very consistent amount of revenues since FY 07. I think it is fair to have expectations of another solid release of financials this upcoming 4th quarter financials expected to be released any day.

Something else special to note from the 10Q mentioned above is that for the year ended June 30, 2009, AVMD’s Revenues were approximately $53.4 million. As you can see from the chart above, it is fair to expect something similar or solid enough to show that AVDM is very much still undervalued here at this .13 per share price range. AVMD is a true sleeper in my opinion that is totally under the radar of many investors.

v/r
Sterling

Quelle: investorshub.advfn.com/boards/read_msg.aspx?message_id=46640557

... und das sieht nicht so gut aus

www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7099913


Hummel